{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:06:47Z","timestamp":1789654007951,"version":"4.0.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Recombinant adeno-associated virus (rAAV) vectors underpin many approved and late-stage gene therapies, yet manufacturing costs remain a major driver of therapy price. Here, we present the first comprehensive, platform-resolved cost analysis of rAAV production across three industrially relevant suspension platforms: transient transfection, baculovirus infection, and producer cell line (PCL). Using a bottom-up model, we decompose total cost-of-goods (COGs) into upstream, downstream, drug product, and quality control contributions at bioreactor scales from 50\u2009L to 2000 L. We show that, on a per-batch basis, baculovirus infection is the most cost-efficient platform, followed by transient transfection and PCLs however, when costs are normalized to vector titer (cost per 1 \u00d7 10\u00b9\u00b2 vg), the ranking shifts, with transient transfection becoming the lowest-cost platform under the modeled assumptions, followed by baculovirus infection and PCL platforms, underscoring the dominant influence of productivity on unit cost. We identify platform-specific cost drivers\u2014plasmids, transfection reagent, and media in transient transfection; media and perfusion consumables in PCL platforms; and affinity capture chromatography in baculovirus processes\u2014with buffer preparation consistently representing the largest downstream material cost across platforms. We further quantify the impact of process development levers: transfection optimization and perfusion-based intensification reduce cost per dose by up to an order of magnitude, whereas affinity resin reuse and capsid enrichment strategies provide modest, incremental savings. Incorporating indication-specific annual viral genome demand reveals how process optimization and scale-up together reduce batch burden and lower dose cost by up to two orders of magnitude, suggesting the potential for improved supply feasibility, even for high-dose neuromuscular indications, under the modeled assumptions of productivity improvement and process optimization. Together, these results provide a quantitative framework linking platform choice, process scale, and unit operations to rAAV manufacturing COGs.<\/jats:p>","DOI":"10.1038\/s41434-026-00631-3","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:00:09Z","timestamp":1784606409000},"page":"559-570","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["rAAV production cost analysis: Indication-specific cost per dose and reduction strategies"],"prefix":"10.1038","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4644-362X","authenticated-orcid":false,"given":"Min Tae","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8164-0478","authenticated-orcid":false,"given":"Dan","family":"Matuszek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1233-8412","authenticated-orcid":false,"given":"Angela","family":"Andaluz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3768-789X","authenticated-orcid":false,"given":"Seyed Pouria","family":"Motevalian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"631_CR1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","volume":"9","author":"J-H Wang","year":"2024","unstructured":"Wang J-H, Gessler DJ, Zhan W, Gallagher TL, Gao G. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduct Target Ther. 2024;9:78.","journal-title":"Signal Transduct Target Ther"},{"key":"631_CR2","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/j.ymthe.2025.03.064","volume":"33","author":"L Suarez-Amaran","year":"2025","unstructured":"Suarez-Amaran L, Song L, Tretiakova AP, Mikhail SA, Samulski RJ. AAV vector development, back to the future. Mol Ther. 2025;33:1903\u201336.","journal-title":"Mol Ther"},{"key":"631_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.cytogfr.2024.09.003","volume":"80","author":"D Liu","year":"2024","unstructured":"Liu D, Li T, Liu L, Che X, Li X, Liu C, et al. Adeno-associated virus therapies: Pioneering solutions for human genetic diseases. Cytokine & Growth Factor Rev. 2024;80:109\u201320.","journal-title":"Cytokine & Growth Factor Rev"},{"key":"631_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2024.101403","volume":"33","author":"D Berry","year":"2025","unstructured":"Berry D, Hickey C, Kahlman L, Long J, Markus C, McCombs CK. Ensuring patient access to gene therapies for rare diseases: Navigating reimbursement and coverage challenges. Mol Ther Methods Clin Dev. 2025;33:101403.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"631_CR5","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2024-0118","volume":"13","author":"S Phares","year":"2024","unstructured":"Phares S, Trusheim M, Emond SK, Pearson SD. Managing the challenges of paying for gene therapy: strategies for market action and policy reform. J Comp Eff Res. 2024;13:e240118.","journal-title":"J Comp Eff Res"},{"key":"631_CR6","doi-asserted-by":"publisher","first-page":"479","DOI":"10.18609\/cgti.2024.061","volume":"10","author":"G Thakur","year":"2024","unstructured":"Thakur G, Mink S, Bak H, Tustian AD. Improving process efficiency to reduce cost-of-goods per dose in manufacturing of recombinant AAVs. Cell Gene Ther Insights. 2024;10:479\u201399.","journal-title":"Cell Gene Ther Insights"},{"key":"631_CR7","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/j.tibtech.2025.02.016","volume":"43","author":"MT Park","year":"2025","unstructured":"Park MT, Verma A, Froelich CA, Motevalian SP. Process and quality considerations for recombinant adeno-associated virus manufacturing platforms. Trends Biotechnol. 2025;43:1921\u201337.","journal-title":"Trends Biotechnol"},{"key":"631_CR8","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.18609\/cgti.2019.175","volume":"5","author":"E Cameau","year":"2019","unstructured":"Cameau E, Glover C, Pedregal A. Cost modelling comparison of adherent multi-trays with suspension and fixed-bed bioreactors for the manufacturing of gene therapy products. Cell Gene Ther Insights. 2019;5:1663\u201374.","journal-title":"Cell Gene Ther Insights"},{"key":"631_CR9","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1002\/bit.70052","volume":"122","author":"A Andaluz","year":"2025","unstructured":"Andaluz A, Monteverde B, Vera K, Tse B, Gajic I, Forelich C, et al. Accelerated adeno associated virus upstream process development from high-throughput systems to clinical scale. Biotechnol Bioeng. 2025;122:3051\u201360.","journal-title":"Biotechnol Bioeng"},{"key":"631_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.994743","volume":"10","author":"M Hong","year":"2022","unstructured":"Hong M, Li T, Xue W, Zhang S, Cui L, Wang H, et al. Genetic engineering of baculovirus-insect cell system to improve protein production. Front Bioeng Biotechnol. 2022;10:994743.","journal-title":"Front Bioeng Biotechnol"},{"key":"631_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1302648","volume":"11","author":"N Luo","year":"2024","unstructured":"Luo N, Chen X, Li J, Huynh D, Li Y, Ou L, et al. Evaluation of recombinant baculovirus clearance during rAAV production in Sf9 cells using a newly developed fluorescent-TCID50 assay. Front Med. 2024;11:1302648.","journal-title":"Front Med"},{"key":"631_CR12","unstructured":"Hoeksema F, van der Schaar H, Puri P, Marsden S R, van Deventer S, Martens D, et al. Large-scale AAV production: Advantages of an insect-cell baculovirus expression vector platform. https:\/\/www.bioprocessintl.com\/expression-platforms\/large-scale-aav-production-advantages-of-an-insect-cell-baculovirus-expression-vector-platform: Bioprocess Int; 2023."},{"key":"631_CR13","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3390\/microorganisms12020384","volume":"12","author":"O-W Merten","year":"2024","unstructured":"Merten O-W. Development of stable packaging and producer cell lines for the production of AAV vectors. Microorganisms. 2024;12:384.","journal-title":"Microorganisms"},{"key":"631_CR14","first-page":"18","volume":"17","author":"DAAV Smith","year":"2017","unstructured":"Smith DAAV. vector manufacturing\u2013challenges & opportunities in the manufacturing of AAV vectors used in the delivery of gene therapy treatments. Drug Dev Deliv. 2017;17:18\u201324.","journal-title":"Drug Dev Deliv"},{"key":"631_CR15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ymthe.2023.11.022","volume":"32","author":"S Liu","year":"2024","unstructured":"Liu S, Li J, Peraramelli S, Luo N, Chen A, Dai M, et al. Systematic comparison of rAAV vectors manufactured using large-scale suspension cultures of Sf9 and HEK293 cells. Mol Ther. 2024;32:74\u201383.","journal-title":"Mol Ther"},{"key":"631_CR16","doi-asserted-by":"publisher","first-page":"684","DOI":"10.2174\/1389201016666150505122228","volume":"16","author":"W Qu","year":"2015","unstructured":"Qu W, Wang M, Wu Y, Xu R. Scalable downstream strategies for purification of recombinant adeno-associated virus vectors in light of the properties. Curr Pharm Biotechnol. 2015;16:684\u201395.","journal-title":"Curr Pharm Biotechnol"},{"key":"631_CR17","unstructured":"Daniels G. Case Study: Comparability between HEK293 and Sf9-baculovirus AAV manufacturing processes; Available from: https:\/\/www.casss.org\/docs\/default-source\/cgtp-summit\/2023-speaker-presentations\/daniels-garrett-prevail-therapeutics-2023.pdf?sfvrsn=1754b96e_6. 2023."},{"key":"631_CR18","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1021\/acssynbio.2c00207","volume":"11","author":"Z Lee","year":"2022","unstructured":"Lee Z, Lu M, Irfanullah E, Soukup M, Hu W-S. Construction of an rAAV producer cell line through synthetic biology. ACS Synth Biol. 2022;11:3285\u201395.","journal-title":"ACS Synth Biol"},{"key":"631_CR19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.tibtech.2010.02.001","volume":"28","author":"AA Shukla","year":"2010","unstructured":"Shukla AA, Th\u00f6mmes J. Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends Biotechnol. 2010;28:253\u201361.","journal-title":"Trends Biotechnol"},{"key":"631_CR20","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.chroma.2016.06.084","volume":"1459","author":"M Pathak","year":"2016","unstructured":"Pathak M, Rathore AS. Mechanistic understanding of fouling of protein A chromatography resin. J Chromatogr A. 2016;1459:78\u201388.","journal-title":"J Chromatogr A"},{"key":"631_CR21","unstructured":"Walsh G. Biopharmaceuticals: biochemistry and biotechnology. 2nd ed. John Wiley & Sons, 2013."},{"key":"631_CR22","unstructured":"BioPhorum. Strategies for minimizing the impact of bioburden and sterility testing on gene therapy batch yield. https:\/\/www.cellandgene.com\/doc\/strategies-for-minimizing-the-impact-of-bioburden-and-sterility-testing-on-gene-therapy-batch-yield-0001: Cell&Gene; 2024."},{"key":"631_CR23","unstructured":"United States Pharmacopeial Convention. USP 43, NF38: The United States Pharmacopeia, the National Formulary. United States Pharmacopeial Convention, 2019."},{"key":"631_CR24","first-page":"28","volume":"28","author":"DG Bracewell","year":"2015","unstructured":"Bracewell DG, Pathak M, Ma G, Rathore A. Re-use of protein A resin: fouling and economics. BioPharm Int. 2015;28:28\u201333.","journal-title":"BioPharm Int"},{"key":"631_CR25","doi-asserted-by":"publisher","first-page":"489","DOI":"10.18609\/cgti.2025.059","volume":"11","author":"D Dulac","year":"2025","unstructured":"Dulac D. Efficient AAV purification: resin reuse and scalable polish method. Cell Gene Ther Insights. 2025;11:489\u2013503.","journal-title":"Cell Gene Ther Insights"},{"key":"631_CR26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12929-025-01123-z","volume":"32","author":"Y-F Wu","year":"2025","unstructured":"Wu Y-F, Chen J-A, Jong Y-J. Treating neuromuscular diseases: unveiling gene therapy breakthroughs and pioneering future applications. J Biomed Sci. 2025;32:30.","journal-title":"J Biomed Sci"},{"key":"631_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1561216","volume":"13","author":"X Guo","year":"2025","unstructured":"Guo X, Liu X, Lin J, Huang Z, Lin S, Zhang M, et al. Global, regional, and national burden of four major neurological diseases in women from 1990 to 2021. Front Public Health. 2025;13:1561216.","journal-title":"Front Public Health"},{"key":"631_CR28","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/s41434-023-00392-3","volume":"30","author":"L Witkowsky","year":"2023","unstructured":"Witkowsky L, Norstad M, Glynn AR, Kliegman M. Towards affordable CRISPR genomic therapies: a task force convened by the Innovative Genomics Institute. Gene Ther. 2023;30:747\u201352.","journal-title":"Gene Ther"},{"key":"631_CR29","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s12325-021-02036-7","volume":"39","author":"JM Sallum","year":"2022","unstructured":"Sallum JM, Kaur VP, Shaikh J, Banhazi J, Spera C, Aouadj C, et al. Epidemiology of mutations in the 65-kDa retinal pigment epithelium (RPE65) gene-mediated inherited retinal dystrophies: a systematic literature review. Adv Ther. 2022;39:1179\u201398.","journal-title":"Adv Ther"},{"key":"631_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01430-8","volume":"15","author":"S Crisafulli","year":"2020","unstructured":"Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifir\u00f2 G. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J Rare Dis. 2020;15:141.","journal-title":"Orphanet J Rare Dis"},{"key":"631_CR31","unstructured":"ICER. Therapies for the treatment of spinal muscular atrophy; Available from: https:\/\/icer.org\/wp-content\/uploads\/2025\/01\/ICER_SMA_Draft-Scope_For-Publication_010625.pdf. 2025."},{"key":"631_CR32","unstructured":"Boxe A. Understanding hemophilia prevalence. https:\/\/hemophilianewstoday.com\/hemophilia-prevalence\/: Hemophilia News Today; 2025."},{"key":"631_CR33","unstructured":"The Lancet Neurology: Neurological conditions now leading cause of ill health and disability globally, affecting 3.4 billion people worldwide. 2024. https:\/\/www.healthdata.org\/news-events\/newsroom\/news-releases\/lancet-neurology-neurological-conditions-now-leading-cause-ill N\/AIHME."}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00631-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00631-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00631-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T13:58:39Z","timestamp":1789653519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00631-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["631"],"URL":"https:\/\/doi.org\/10.1038\/s41434-026-00631-3","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest. Consumables from Thermo Fisher Scientific and other suppliers were used as required for process development and analytical testing.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study did not involve human participants, human material, human data, identifiable human images, or live vertebrate animals. Therefore, ethics committee approval and informed consent were not required. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}